Advanced BioScience Laboratories

Advanced BioScience Laboratories, Inc (ABL) is a leading contract research and manufacturing organization, that partners with our clients to support their vaccine and therapeutic development programs. We offer a unique combination of preclinical and clinical services designed to first address the scientific challenges often encountered during proof-of-concept, and then streamline process development and cGMP production of clinical supply.
ABL can assist with all aspects of production development including, but not limited to:
Basic and translational research
Vaccine and therapeutic product design
Animal models for preclinical evaluation including immunomonitoring , efficacy and potency
Cell line and process development
cGMP manufacture of cell banks and virus banks
cGMP manufacture of clinical supply for protein therapeutics, vaccines and live viral vectors

Ask about our 9,000 sq ft clinical GCLP immunomonitoring space and our vaccine and therapeutic testing services.

With a 50+ year history as a service provider to the life sciences industry, ABL brings a broad technical knowledge base, highly experienced work force, and seasoned project management to every program. Our goal is to become a seamless extension of our clients’ product development group – helping them advance today’s ideas into tomorrow’s medicines. Our history, capabilities and expertise allow ABL to provide solution based services to our clients.

DP Clinical, Inc. is a privately held Contract Research Organization (CRO) specializing in neurology/CNS (including spinal cord injury), oncology, ophthalmology, infectious disease/vaccines, and rare disease Phase I-IV clinical programs. DP Clinical provides a full complement of clinical trial services to pharmaceutical, biotech, and medical device companies including trial management, monitoring, data management, biostatistics, regulatory, safety monitoring and reporting, and medical writing. Since 1994, we have worked for clients of all sizes — small to large pharmaceutical and biotech companies, academic research institutions, and government sponsors.

DP Clinical provides integrated trial solutions as well as specific service components based on sponsor need. Our comprehensive services include:
• Project management
• Clinical trial monitoring
• Data management
• Biostatistics
• Pharmacovigilance and safety
• Regulatory affairs
• Quality assurance
• Medical writing

ECLA is an Academic Research Organization devoted to provide support and expertise for the conduct of clinical trials in Latin America.

With headquarters located in Rosario, Argentina, offices in Montevideo -Uruguay and local representations in Sao Paulo-Brazil, Temuco-Chile, Lima-Peru, Bucaramanga-Colombia and Quito-Ecuador, ECLA leads the coordination of clinical trials in the region.

In the early days of 1987, ECLA designed and conducted the first full-scale clinical trial in the setting of acute myocardial infarction in collaboration with Oxford University, UK. Since then, more than 30.000 patients have been enrolled in controlled clinical trials.

ECLA helps the pharmaceutical industry in its efforts to bring cutting edge therapies to the marketplace by providing a wide range of services:
- Academic leadership
- Project, site and regulatory management
- Monitoring
- Quality Assurance
- Pharmacy
- Financial and legal assistance
- Data management and statistical support

ECLA has been collaborating with worldwide academic organizations and pharmaceutical companies for the design, set up and conduct of clinical trials in the following therapeutic areas: cardiology, diabetes, epidemiology, oncology, neurology, pneumology and vaccines.

ECLA is an Academic Research Organization devoted to provide support and expertise for the conduct of clinical trials in Latin America.

With headquarters located in Rosario, Argentina, offices in Montevideo -Uruguay and local representations in Sao Paulo-Brazil, Temuco-Chile, Lima-Peru, Bucaramanga-Colombia and Quito-Ecuador, ECLA leads the coordination of clinical trials in the region.

In the early days of 1987, ECLA designed and conducted the first full-scale clinical trial in the setting of acute myocardial infarction in collaboration with Oxford University, UK. Since then, more than 30.000 patients have been enrolled in controlled clinical trials.

ECLA helps the pharmaceutical industry in its efforts to bring cutting edge therapies to the marketplace by providing a wide range of services:
- Academic leadership
- Project, site and regulatory management
- Monitoring
- Quality Assurance
- Pharmacy
- Financial and legal assistance
- Data management and statistical support

ECLA has been collaborating with worldwide academic organizations and pharmaceutical companies for the design, set up and conduct of clinical trials in the following therapeutic areas: cardiology, diabetes, epidemiology, oncology, neurology, pneumology and vaccines.

Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc., Akston’s COVID-19 vaccine candidate is in Phase II trials in the Netherlands. It has partnered with Dechra Pharmaceuticals PLC to commercialize once-a-week canine and feline insulin therapies. The company employs 35 people, has over 3,500 ft2 of research laboratory space and a 12,400 ft2 GMP clean room biologics manufacturing facility.